1.33
-0.08(-5.67%)
Currency In USD
| Previous Close | 1.41 |
| Open | 1.41 |
| Day High | 1.43 |
| Day Low | 1.32 |
| 52-Week High | 4.42 |
| 52-Week Low | 0.85 |
| Volume | 519,970 |
| Average Volume | 504,534 |
| Market Cap | 60.79M |
| PE | -1.41 |
| EPS | -0.94 |
| Moving Average 50 Days | 1.44 |
| Moving Average 200 Days | 1.92 |
| Change | -0.08 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) since IPO date, it would be worth $6.05 as of July 01, 2025 at a share price of $1.33. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $773.26 as of July 01, 2025 at a share price of $1.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
GlobeNewswire Inc.
Jun 09, 2025 12:00 PM GMT
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PRINCETON, N.
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
May 22, 2025 9:26 PM GMT
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment